Literature DB >> 17320951

Peg-filgrastim versus filgrastim after autologous stem cell tranplantation: case-control study in patients with multiple myeloma and review of the literature.

Pellegrino Musto1, Potito Rosario Scalzulli, Elisabetta Terruzzi, Fausto Rossini, Pasquale Iacopino, Giuseppe Messina, Roberto Guariglia, Giuseppe Pietrantuono, Oreste Villani, Fiorella D'Auria, Antonietta Falcone, Grazia Sanpaolo, Maria Rosa Valvano, Enrico Maria Pogliani, Fortunato Morabito.   

Abstract

We investigated the effects of a single s.c. injection of peg-filgrastim in 32 patients with multiple myeloma who underwent autologous stem cell transplantation (AuSCT) as first line treatment. For comparison, 32 myeloma patients with similar characteristics and receiving standard daily administration of filgrastim were matched. Overall, there were no statistically significant differences between peg-filgrastim and filgrastim in terms of tolerability, marrow recovery, severity of neutropenia, incidence and duration of febrile neutropenia, documented infections and transfusions. However, some favourable trends or effects in favour of peg-filgrastim were observed. This was confirmed by a review of the published papers about this topic.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17320951     DOI： 10.1016/j.leukres.2007.01.008

Source DB:  PubMed          Journal:  Leuk Res        ISSN： 0145-2126            Impact factor:   3.156


  4 in total

1.  Early versus late administration of pegfilgrastim after high-dose chemotherapy and autologous hematopoietic stem cell transplantation.

Authors:  C Kahl; H G Sayer; A Hinke; M Freund; J Casper
Journal:  J Cancer Res Clin Oncol       Date:  2011-12-25       Impact factor: 4.553

Review 2.  Lipegfilgrastim in the management of chemotherapy-induced neutropenia of cancer patients.

Authors:  Roberto Guariglia; Maria Carmen Martorelli; Rosa Lerose; Donatella Telesca; Maria Rita Milella; Pellegrino Musto
Journal:  Biologics       Date:  2016-01-22

3.  A randomized, non-inferiority study comparing efficacy and safety of a single dose of pegfilgrastim versus daily filgrastim in pediatric patients after autologous peripheral blood stem cell transplant.

Authors:  Simone Cesaro; Francesca Nesi; Gloria Tridello; Massimo Abate; Irene Sara Panizzolo; Rita Balter; Elisabetta Calore
Journal:  PLoS One       Date:  2013-01-07       Impact factor: 3.240

4.  Efficacy of deferred dosing of granulocyte colony-stimulating factor in autologous hematopoietic transplantation for multiple myeloma.

Authors:  J E Cox; S Campos; J Wu; R May; H Liu; C A Ramos; G Carrum; H E Heslop; M K Brenner; R T Kamble
Journal:  Bone Marrow Transplant       Date:  2013-10-07       Impact factor: 5.483
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.